Anavex Life Sciences has filed a patent for a dosage form that combines A19-144 or A2-73 with an anti-epilepsy drug (AED) to treat seizures. The method involves administering a therapeutically effective amount of the compound along with the AED. GlobalData’s report on Anavex Life Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Anavex Life Sciences, Cancer treatment biomarkers was a key innovation area identified from patents. Anavex Life Sciences's grant share as of September 2023 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
The patent is filed for a method of treating seizures
A recently filed patent (Publication Number: US20230301961A1) describes a method for treating seizures in individuals in need of such treatment. The method involves administering a therapeutically effective amount of a compound called 1-(2,2-diphenyltetrahydrofuran-3-yl)-N,N-dimethylmethanamine or its pharmaceutically acceptable salt. Additionally, at least one anti-epilepsy drug (AED) is administered alongside this compound.
The patent claims specify various aspects of the method. For instance, the pharmaceutically acceptable salt used can be the hydrochloride salt (A2-73). The method can be applied to epilepsy patients, suspected epilepsy patients, or even individuals without a diagnosis of epilepsy. It is worth noting that the method can be particularly suitable for pediatric patients.
The frequency of administration of the compound or its salt can be daily or once every two days. Importantly, the administration of the AED is coordinated or co-timely with the administration of the compound or its salt. This coordination ensures optimal treatment outcomes.
One significant advantage of this method is that the subject does not experience a decrease in memory after the administration of the AED, compared to before the administration. This is an important consideration for individuals undergoing seizure treatment.
The patent also lists a wide range of AEDs that can be used in combination with the compound or its salt. These include Acetazolamide, Clonazepam, Diazepam, Lamotrigine, Phenobarbital, Pregabalin, Topiramate, and many others. The method allows for the administration of these AEDs in sub-therapeutic amounts, which can be less than the therapeutically effective amount when used alone.
Another embodiment of the method involves the administration of a low dose of donepezil in conjunction with the compound or its salt. The therapeutic effective amount of the compound is specified to be between 0.5-10 mg/day, while the low dose of donepezil is about 4 mg/day.
Overall, this patent presents a method for treating seizures that involves the administration of a specific compound or its salt alongside one or more AEDs. The method offers potential benefits for epilepsy patients, including pediatric patients, and aims to minimize memory-related side effects.
To know more about GlobalData’s detailed insights on Anavex Life Sciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
